Scroll Back to Top
clonoseq logo

The First and Only FDA-cleared Assay for Measurable Residual Disease Detection

MRD detection in bone marrow from patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).

MRD: A powerful way to assess response
and predict patient outcomes

Measurable (or minimal) residual disease (MRD) refers to the small number of cancer cells that may remain in a patient’s body during and after treatment. Clinical practice guidelines recognize that MRD status is a reliable indicator of clinical outcome and response to therapy in myeloma, ALL and CLL patients.1,2,3,4

The clonoSEQ® Assay is an MRD assessment tool powered by next-generation sequencing (NGS) technology and differentiated from other NGS assays by groundbreaking advances in chemistry and proprietary bioinformatics.5,6

Clinicians who leverage the latest advances in
personalized medicine use clonoSEQ to:5



long-term outcomes



treatment response



disease burden



potential relapse

Why choose clonoSEQ?5, 6

Deep Sensitivity

Able to detect one cancerous cell in 1 million normal cells*

Broad patient experience

>15,000 patients tested to date

Reliable results

First and only FDA-cleared MRD assay; demonstrates accuracy, precision, and reproducibility

Widely utilized by experts

30 out of 30 NCCN institutions currently using in clinical trials and/or clinical practice

Streamlined ordering

Samples collected will be sent to Adaptive Biotechnologies for testing. clonoSEQ will be performed, reported, and billed by Adaptive. Labcorp insurance contracts do not apply. Adaptive Biotechnologies and Labcorp are independent providers. 

NCCN Guidelines

NGS MRD testing incorporated in NCCN guidelines for myeloma, ALL and CLL1,2,3,4

How clonoSEQ Works5

Clonality (ID) Test

Identifies trackable malignant DNA sequence(s) in a high disease load sample collected at the time of diagnosis or relapse

Tracking (MRD) Test

Quantifies and tracks MRD during or after treatment in a freshly-drawn bone marrow or blood sample